• BMS-345541 Hydrochloride: IKK Evidence Guide

  2026-10-08

  BMS-345541 hydrochloride is an allosteric IKK inhibitor used to study NF-κB signaling. Evidence supports its value as a mechanistic research tool, while direct evidence for airway restenosis and clinical treatment remains absent.

• PD 0332991 in Cisplatin-Resistant NSCLC Research

  2026-10-08

  PD 0332991, also known as palbociclib, is a selective CDK4/6 inhibitor studied as a cell-cycle-directed research tool. In a 2021 lung-cancer study, PD 0332991 enhanced cisplatin-associated growth inhibition in A549 and cisplatin-resistant A549/CDDP cells, with reported changes in apoptosis and G0/G1 arrest. The evidence supports a mechanistic hypothesis involving the Rb–E2F pathway, but remains limited by its in vitro design, narrow model selection, incomplete combination-effect reporting, and lack of clinical validation.

• VX-765 and the Next Phase of Pyroptosis Research

  2026-10-07

  A mechanistic and translational perspective on VX-765, VRT-043198, caspase-1 biology, and the importance of distinguishing cytokine processing from inflammasome-driven cell death.

• Bromodomain Inhibitor, (+)-JQ1: Evidence Overview

  2026-10-07

  A source-grounded overview of (+)-JQ1 as a BET bromodomain research tool, covering its mechanistic rationale, reported application areas, relevance to prostate-cancer heterogeneity, evidence strength, and key limitations.

• SM-102 and the Next Phase of mRNA Delivery

  2026-10-06

  SM-102 is best understood not as a standalone solution, but as a mechanistic component within a broader lipid nanoparticle system. This evidence-led perspective examines its relevance to mRNA delivery, the boundaries of current plant genome-editing evidence, and the translational questions that should shape future development.

• Perospirone: Receptor Pharmacology and Kv1.5 Evidence

  2026-10-06

  Perospirone (SM-9018 free base) is an atypical antipsychotic studied mainly through serotonergic and dopaminergic mechanisms. New evidence from rabbit coronary arterial smooth muscle cells reports concentration-dependent inhibition of voltage-gated Kv currents, with partial pharmacological support for Kv1.5 involvement. The result is mechanistically important but remains preclinical and does not establish clinical cardiovascular risk.

• PFHxS Hepatotoxicity and PPAR Signaling in Zebrafish

  2026-10-05

  A 2024 Environmental Science & Technology study combines transcriptomics, liver pathology, biochemical measurements, targeted gene analysis, pharmacological antagonism, and PPAR-related knockdown to investigate PFHxS toxicity in larval zebrafish. The findings support a mechanistic contribution of PPAR signaling to developmental liver injury, while the early-life-stage fish model limits direct extrapolation to human disease.

• MiR-24-3p, Sp1, and PI3K in Doxorubicin HF

  2026-10-05

  A 2024 Cellular Signalling study identifies a miR-24-3p/Sp1/PI3K regulatory axis in doxorubicin-associated heart failure, linking miRNA activity with cardiac dysfunction, oxidative stress, and cardiomyocyte apoptosis. Its combined animal, cell, molecular, and reporter-assay evidence supports mechanistic follow-up, while remaining preclinical and model-dependent.

• Bay 11-7085: NF-κB Mechanism and Evidence

  2026-10-04

  Bay 11-7085 is a supplier-described NF-κB activation inhibitor and chemical probe for studying inflammatory signaling, cell-cycle regulation, and apoptosis. Its reported pharmacology is useful for pathway-focused research, but model-specific findings should not be interpreted as proof of clinical efficacy or pathway exclusivity.

• PPP1R3G Activates RIPK1 in Cell Death Signaling

  2026-10-03

  The Nature Communications study identifies PPP1R3G and PP1γ as a phosphatase module that removes inhibitory RIPK1 phosphorylation and promotes RIPK1-dependent apoptosis and type I necroptosis. Its genetic, biochemical, pharmacological, and mouse-model evidence connects RIPK1 activation with TNF-driven inflammatory pathology while defining important limits for translation beyond the tested systems.

• (5Z)-7-Oxozeaenol: TAK1 Inhibitor Workflows

  2026-10-02

  Build reproducible inflammation and metabolic-stress assays with (5Z)-7-Oxozeaenol, a selective TAK1 inhibitor that connects proximal kinase control to NF-κB, JNK/p38 MAPK, and COX-2 outputs. This guide distinguishes established product benchmarks from practical starting conditions and shows how to interpret TAK1 activity alongside the AMPK–SQSTM1–NRF2 stress response.

• LY294002: Reversible PI3K Pathway Inhibition

  2026-10-01

  LY294002, also known as 2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one, is a cell-permeable, reversible class I PI3K inhibitor. It is used to interrogate PI3K/Akt/mTOR signaling, apoptosis, autophagy, and ovarian carcinoma research, while its BET bromodomain activity requires careful interpretation.

• (5Z)-7-Oxozeaenol TAK1 Workflows

  2026-10-01

  (5Z)-7-Oxozeaenol enables targeted interrogation of TAK1-dependent inflammatory signaling and its connection to metabolic stress adaptation. This practical guide covers cell-based workflows, AMPK–SQSTM1 assay design, controls, and troubleshooting for interpreting NF-κB, JNK/p38 MAPK, and COX-2 responses.

• Troglitazone Workflows for PPARγ and TAM Research

  2026-09-30

  Troglitazone gives researchers a practical PPARγ-centered perturbation tool for connecting lipid and glucose metabolism with macrophage and renal carcinoma assays. This guide combines formulation, dose-finding, SPP1-reporter workflows, troubleshooting, and evidence-based boundaries for translating metabolic signaling into tumor-microenvironment research.

• Bromodomain Inhibitor (+)-JQ1 and Ferroptosis

  2026-09-30

  Explore how Bromodomain Inhibitor, (+)-JQ1 converts BRD4 inhibition into a ferroptosis-sensitizing strategy through ROS accumulation and FSP1 regulation. This article translates recent mechanistic findings into practical assay and interpretation decisions.

8182 records 1/546 page Next 12345 下5页 Last page